



ABIVAX included in the CAC Small, CAC Mid & Small and CAC All-Tradable indices

Paris, September 14th, 2015 – ABIVAX (Euronext Paris: FR0012333284 - ABVX), a leading clinical stage biotech company developing and commercializing anti-viral compounds and human vaccines, today announced that it will be included in the CAC® Small, CAC® Mid & Small and CAC® All-Tradable indices. This decision was taken by the Scientific Council of Euronext Paris' indices on September 10th. ABIVAX's inclusion in the three indices will take effect on September 18th, 2015 after the close of the Paris stock market.

About ABIVAX

ABIVAX is an advanced clinical development biotech company focused on becoming a global leader in the discovery, development and commercialization of anti-viral compounds and human vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B.

ABIVAX has 2 compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic Hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and vaccines that may enter the clinical stage in the coming 18 months.

ABX464 has been developed using ABIVAX' anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients' clear important pathogenic viruses.

Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy.

ABIVAX was founded by Dr. Philippe Pouletty, M.D., managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation. ABIVAX is listed on the regulated market of Euronext Paris, compartment B (ISIN code: FR0012333284 – Ticker: ABVX). For more information, please visit www.abivax.com.

Contacts

Investor relations

Raquel Lizarraga
raquel.lizarraga@abivax.com
+33 1 53 83 06 93

Press relations

ALIZE RP
Caroline Carmagnol and Florence Portejoie
abivax@alizerp.com
33 (0) 1 44 54 36 64/+33 6 64 18 99 59